X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (57) 57
oncology (38) 38
index medicus (29) 29
cancer (23) 23
female (23) 23
antineoplastic agents - therapeutic use (22) 22
male (19) 19
neoplasms - drug therapy (19) 19
aged (17) 17
middle aged (17) 17
adult (16) 16
receptor, epidermal growth factor - antagonists & inhibitors (13) 13
treatment outcome (13) 13
clinical trials (12) 12
clinical trials as topic (12) 12
quinazolines - therapeutic use (12) 12
tyrosine kinase inhibitor (12) 12
antineoplastic combined chemotherapy protocols - therapeutic use (11) 11
cell lung-cancer (11) 11
hematology, oncology and palliative medicine (10) 10
care and treatment (9) 9
sirolimus - analogs & derivatives (9) 9
chemotherapy (8) 8
expression (8) 8
growth-factor receptor (8) 8
research (8) 8
sirolimus - therapeutic use (8) 8
aged, 80 and over (7) 7
mutations (7) 7
neoplasm recurrence, local - drug therapy (7) 7
acquired-resistance (6) 6
animals (6) 6
antineoplastic agents - adverse effects (6) 6
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
disease-free survival (6) 6
erlotinib (6) 6
erlotinib hydrochloride (6) 6
gefitinib (6) 6
maximum tolerated dose (6) 6
protein kinase inhibitors - therapeutic use (6) 6
quinazolines - administration & dosage (6) 6
quinazolines - adverse effects (6) 6
trial (6) 6
antineoplastic agents - pharmacology (5) 5
brain neoplasms - drug therapy (5) 5
carcinoma, non-small-cell lung - drug therapy (5) 5
cetuximab (5) 5
disease progression (5) 5
follow-up studies (5) 5
lung neoplasms - drug therapy (5) 5
mtor (5) 5
mutation (5) 5
neoplasm metastasis (5) 5
neoplasm staging (5) 5
neoplasms - genetics (5) 5
oncology, experimental (5) 5
temsirolimus (5) 5
tor serine-threonine kinases (5) 5
antibodies, monoclonal, humanized (4) 4
antimitotic agents (4) 4
antineoplastic agents (4) 4
antineoplastic combined chemotherapy protocols - pharmacokinetics (4) 4
antitumor-activity (4) 4
carcinoma (4) 4
clinical trials as topic - methods (4) 4
drug design (4) 4
drug development (4) 4
epidermal growth factor (4) 4
kinase inhibitor (4) 4
mammalian target (4) 4
medical research (4) 4
medicine & public health (4) 4
monoclonal-antibody (4) 4
pharmacology & pharmacy (4) 4
rapamycin (4) 4
sirolimus - adverse effects (4) 4
sirolimus - pharmacology (4) 4
survival analysis (4) 4
therapy (4) 4
tumors (4) 4
administration, oral (3) 3
adolescent (3) 3
antibodies, monoclonal - therapeutic use (3) 3
antineoplastic agents - administration & dosage (3) 3
antineoplastic agents - pharmacokinetics (3) 3
bevacizumab (3) 3
biomarkers (3) 3
brain neoplasms - pathology (3) 3
breast cancer (3) 3
breast neoplasms - drug therapy (3) 3
carcinoma, hepatocellular - radiotherapy (3) 3
cci-779 (3) 3
child (3) 3
child, preschool (3) 3
drug therapy (3) 3
enzyme inhibitors - therapeutic use (3) 3
everolimus (3) 3
genomics (3) 3
glioblastoma - drug therapy (3) 3
health aspects (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Reviews Drug Discovery, ISSN 1474-1776, 08/2006, Volume 5, Issue 8, pp. 649 - 659
Journal Article
Journal Article
The lancet oncology, ISSN 1470-2045, 2009, Volume 10, Issue 3, pp. 247 - 257
Summary Background Epidermal growth factor receptor (EGFR) is a validated target in squamous-cell carcinoma of the head and neck, but in patients with... 
Hematology, Oncology and Palliative Medicine | BREAST-CANCER CELLS | CETUXIMAB | THERAPY | ONCOLOGY | ACQUIRED-RESISTANCE | TYROSINE KINASE INHIBITOR | II TRIAL | ANTITUMOR-ACTIVITY | CHEMOTHERAPY | EGFR | ENDOTHELIAL GROWTH-FACTOR | Erlotinib Hydrochloride | Multivariate Analysis | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Bevacizumab | Antibodies, Monoclonal, Humanized | Carcinoma, Squamous Cell - mortality | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Vascular Endothelial Growth Factor Receptor-2 - analysis | Head and Neck Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - analysis | Regression Analysis | Carcinoma, Squamous Cell - drug therapy | Transforming Growth Factor alpha - analysis | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Head and Neck Neoplasms - mortality | Care and treatment | Carcinoma | Biological products | Oncology, Experimental | Metastasis | Research | Endothelium | Epidermal growth factor | Erlotinib | Universities and colleges | Health aspects | Vascular endothelial growth factor | Cancer | Index Medicus
Journal Article
International journal of cancer, ISSN 0020-7136, 2013, Volume 132, Issue 7, pp. 1547 - 1555
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2004, Volume 22, Issue 1, pp. 133 - 142
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2007, Volume 25, Issue 25, pp. 3978 - 3984
Journal Article
Journal Article